Gestiva Passes Cmte. Review, But Further Study Of Miscarriage Risk Requested
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Reproductive Health Advisory Committee votes that safety and efficacy of Adeza’s preterm birth agent Gestiva have been demonstrated.
You may also be interested in...
KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval
Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.
KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval
Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.
KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval
NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.